Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Intravenous infusion of allogeneic mesenchymal stromal cells in refractory or relapsed aplastic anemia

Texto completo
Autor(es):
Cle, Diego V. [1, 2] ; Santana-Lemos, Barbara [1, 2] ; Tellechea, Maria Florencia [1] ; Prata, Karen L. [1] ; Orellana, Maristela D. [1] ; Covas, Dimas T. [1, 2] ; Calado, Rodrigo T. [1, 2]
Número total de Autores: 7
Afiliação do(s) autor(es):
[1] Sao Paulo Res Fdn FAPESP, Ctr Cell Based Therapy, Ribeirao Preto, SP - Brazil
[2] Univ Sao Paulo, Ribeir Preto Sch Med, Dept Internal Med, BR-14049 Ribeirao Preto, SP - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Fonte: CYTOTHERAPY; v. 17, n. 12, p. 1696-1705, DEC 2015.
Citações Web of Science: 10
Resumo

Background aims. For patients with aplastic anemia (AA) who are refractory to anti-thymocyte globulin (ATG) and cyclosporine, a second course of immunosuppression is successful in only one-fourth to one-third of cases. Methods. We conducted a phase 1/2 study to evaluate the addition of two to five weekly intravenous infusions of allogeneic unrelated non human leukocyte antigen matched bone marrow derived mesenchymal stromal cells (MSCs) (median, 2.7 x 10(6) cells/kg/infusion; range, 1.3-4.5) to standard rabbit ATG and cyclosporine in nine patients with refractory or relapsed AA. Results. After a median follow-up of 20 months, no infusion-related adverse event was observed, but four deaths occurred as the result of heart failure and bacterial or invasive fungal infections; only two patients achieved partial hematologic responses at 6 months. We failed to demonstrate by fluorescence in situ hybridization or variable number tandem repeat any MSC engraftment in patient marrow 30, 90 or 180 days after infusions. Conclusions. Infusion of allogeneic MSCs in AA is safe but does not improve clinical hematologic response or engraft in recipient bone marrow. This study was registered at clinicaltrials.gov, identifier: NCT01297972. (AU)

Processo FAPESP: 13/08135-2 - CTC - Centro de Terapia Celular
Beneficiário:Dimas Tadeu Covas
Linha de fomento: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs